Compare Gemini Space Station Inc (GEMI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gemini Space Station Inc trades at $4.58 (market cap $590.44M), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| GEMI | XBI | |
|---|---|---|
Market Cap | $590.44M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $32.52 | $164.28 |
52-Week Low | $3.91 | $85.16 |
Enterprise Value | $580.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.69, up 8.06% in the past 24 hours, with a bullish technical signal but weak fundamentals. The company reported a net loss of $582.81 million in 2025 on $179.57 million revenue, with negative profit margins and cash burn from operations. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May-July 2026.
Outlook remains challenged by persistent losses and legal risks, though analyst consensus suggests modest upside to a $5.88 price target. Investment opportunity hinges on execution turnaround, but high operational and litigation risks warrant caution for stock investors.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
